Rachel Yoder

Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer

Priyanka Sharma, Shane R. Stecklein, Rachel Yoder et al. · JAMA Oncology · 2023 · 135 citations · Full text

Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)

Priyanka Sharma, Bruce F. Kimler, Anne O’Dea et al. · Clinical Cancer Research · 2020 · 105 citations · Full text

Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer

Priyanka Sharma, Vandana G. Abramson, Anne O’Dea et al. · Clinical Cancer Research · 2021 · 82 citations · Full text

Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer

Rachel Yoder, Bruce F. Kimler, Joshua M. Staley et al. · npj Breast Cancer · 2022 · 67 citations · Full text

Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT).

Priyanka Sharma, Shane R. Stecklein, Rachel Yoder et al. · Journal of Clinical Oncology · 2022 · 51 citations

Breast Oncology, Cancer Management, Immunology +20